DURECT (DRRX)
(Delayed Data from NSDQ)
$1.69 USD
+0.13 (8.33%)
Updated Jun 13, 2024 04:00 PM ET
After-Market: $1.70 +0.01 (0.59%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
DURECT Corporation [DRRX]
Reports for Purchase
Showing records 121 - 140 ( 142 total )
Company: DURECT Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: DURECT Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: DURECT Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: DURECT Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: DURECT Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: DURECT Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: DURECT Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: DURECT Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: DURECT Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: DURECT Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: DURECT Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: DURECT Corporation
Industry: Medical - Drugs
Company: DURECT Corporation
Industry: Medical - Drugs
Company: DURECT Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: DURECT Corporation
Industry: Medical - Drugs
Company: DURECT Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: DURECT Corporation
Industry: Medical - Drugs
C. K. COOPER DURECT CORPORATION INITIATING COVERAGE
Provider: C.K. Cooper and Company
Analyst: TRBOVICH K
Company: DURECT Corporation
Industry: Medical - Drugs
Second Quarter Earnings were a Non Event from a Numbers Perspective, but the Pipeline Progress Continues.
Provider: WEDBUSH SECURITIES INC.
Analyst: BANK P
Company: DURECT Corporation
Industry: Medical - Drugs
PECIALTY PHARMACEUTICALS:Do Your Homework Over the Summer Because the Fall Will Be Explosive with Major PDUFA Activity
Provider: WEDBUSH SECURITIES INC.
Analyst: BANK P
Company: DURECT Corporation
Industry: Medical - Drugs
Hospira Deal Appears To Be A Good Strategic Fit In Our View Based On Takeaways From A Recent Management Call.
Provider: WEDBUSH SECURITIES INC.
Analyst: BANK P